New Market Research Report: United Arab Emirates Pharmaceuticals & Healthcare Report Q3 2014

The UAE is one of the more developed markets in the Middle East and has a strong existing healthcare infrastructure. As the UAE is aiming to introduce comprehensive health insurance throughout the country , allowing businesses to shoulder much of the cost of this expanded coverage, the government will gradually contribute less to the country's healthcare spending. Between 2013 and 2018, we expect private sector healthcare spending to outpace public. However, the public sector will remain the main source of healthcare expenditure, contributing over 60% of total spending by 2023.

Headline Expenditure Projections:

* Pharmaceuticals: AED7.02bn (USD1.91bn) in 2013 to AED7.44bn (USD2.03bn) in 2014; +6.0% in local currency and +6.1% in US dollar terms. Forecast in line with previous quarter.
* Healthcare: AED42.60bn (USD11.60bn) in 2013 to AED45.82bn (USD12.48bn) in 2014; +7.6% in local currency terms and US dollar terms. Forecast revised down from previous quarter due to recently released WHO data.

Full Report Details at
- http://www.fastmr.com/prod/852008_united_arab_emirates_pharmaceuticals_healthcare.aspx?afid=301

Risk/Reward Rating

The UAE has moved up one place in our Pharmaceutical Risk/Reward Rating (RRR). In Q3 2014 it ranks third out of a total of 30 markets in the Middle East and Africa region, with a score of 57.4.

Key Trends & Developments

June

The UAE is among the first five countries in the Arab world to implement an updated and more stringent set of healthcare measures, which will be effective from July 1 2015, reports Gulf Today. The new measures will guarantee public health safety and benefits, in the midst of an increasing number of drugs and treatment methods flooding the market. The main aim is to ensure that all pharmaceutical products entering the region are safe and effective, so that the increasing incidence of disease is mitigated. May

The UAE's health ministry announced that rotavirus vaccination is mandatory for all babies in the country, reports the National. The vaccine, which protects against the deadly virus that causes gastroenteritis,...

The United Arab Emirates Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United Arab Emirates Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Emirati pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for United Arab Emirates to test other views - a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- United Kingdom Pharmaceuticals & Healthcare Report Q3 2014
- United States Pharmaceuticals & Healthcare Report Q3 2014
- Iraq Pharmaceuticals & Healthcare Report Q3 2014
- Jordan Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014